— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer by Year End — CAMBRIDGE, Mass., May 10, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc.
Jan. 7, 2011, 8:17 AM EST / Source: GlobeNewswire CAMBRIDGE, Mass., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today provided guidance on its anticipated pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback